Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib?in?Untreated ALK-Positive Advanced Non-Small Cell?Lung Cancer in the Global Phase III ALEX Study.
Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, M?ller B, Shaw AT. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib?in?Untreated ALK-Positive Advanced Non-Small Cell?Lung Cancer in the Global Phase III ALEX Study. J Thorac Oncol. 2019 07; 14(7):1233-1243.